Download this free whitepaper to learn more
Exome and genome sequencing (ES/GS) offer faster, more accurate diagnoses while reducing unnecessary utilization. Yet payor coverage continues to lag despite compelling evidence of clinical and economic benefit.
Download this free white paper to explore:
- How ES/GS improve diagnostic yield across populations with rare disease, neurodevelopmental disorders and in the NICU
- Real-world cost-savings: shorter lengths of stay, fewer low-yield diagnostics, and increased efficiencies
- How fragmented payor policies reduce access, and how alignment with professional guidelines can create better outcomes for patients, providers and payors
Offered Free by: GeneDx
See All Resources from: GeneDx
